IVIG adverse reactions: Potential role of cytokines and vasoactive substances

Vox Sanguinis

Volumn 74, Issue 2, 1998, Pages 74-82

  Bagdasarian, A ^a   Tonetta, S ^a   Harel, W ^a   Mamidi, R ^a   Uemura, Y ^a  

^a Grifols SA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 6; THROMBOXANE B2; VASOACTIVE AGENT;

ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ADULT; CHYMASES; CYTOKINES; DIZZINESS; HEADACHE; HISTAMINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-6; KININOGEN, HIGH-MOLECULAR-WEIGHT; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; NEUTROPHILS; SERINE ENDOPEPTIDASES; THROMBOXANE B2; TIME FACTORS; TRYPTASES; TUMOR NECROSIS FACTOR-ALPHA; VASOMOTOR SYSTEM;

EID: 0031962190     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030909     Document Type: Article

References (48)

1. Barandun S, Kistler P, Jeunet F, Isliker H: Intravenous administration of human gamma globulin. Vox Sang 1962;7:157-174.
2. Buckley RH, Schiff RI: The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-117.
3. Pirofsky B: Intravenous immune globulin therapy in hypogammaglobulinemia: A review. Am J Med 1984;7:1288-1294.
4. Pirofsky B, McKinzey D: Intravenous immune globulins - A review of their uses in selected immunodeficiency and autoimmune diseases. Drugs 1992;43:6-14.
5. Morrel A, Nydegger UE (eds): Clinical Use of Intravenous Immunoglobulins. London, Academic Press, 1986.
6. Knapp MJ, Colburn PA: Clinical uses of intravenous immune globulin. Clin Pharm 1990;9:509-529.
7. Wordell CJ: Use of intravenous immune globulin therapy: An overview. DICP Ann Pharmacother 1991;25:805-817.
8. Kline MK: Intravenous immunoglobulins; in Feign RD: Semin Pediatr Infect Dis. Philadelphia, Saunders 1992, vol 3, pp 141-203.
9. NIH Consensus Conference: Intravenous immunoglobulin: Prevention and treatment of disease. J Am Med Assoc 1990;264:3189-3193.
10. Pacheco SE: The risk of intravenous immunoglobulin preparations; in Feigin RD (ed): Semin Pediatr Infect Dis. Philadelphia, Saunders, 1992, vol 3, pp 147-149.
11. Misbah SA, Chapel HM: Adverse effects of intravenous immunoglobulins. Drug Safety 1993;9:254-262.
12. Barandun S, Isliker H: Development of immunoglobulin preparations for intravenous use. Vox Sang 1986;51:157-160.
13. Schifferili JA: Adverse effects of intravenous immunoglobulins. Trans Sci 1991;13:331-338.
14. Tankersley DL: Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune disease. Immunol Rev 1994;139:159-172.
15. Alving BM, Tankersley DL, Mason BL, Rossi F, Aronson DL, Finlayson JS: Contact-activated factors: Contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J Lab Clin Med 1980;96:334-346.
16. Queseda JR, Talpaz M, Rios A, Kirzrock R, Gutteran JU: Clinical toxicity of interferons in cancer patients. J Clin Oncol 1986;4:234-243.
17. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987;5:1942-1951.
18. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
19. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-1652.
20. 2/B cell stimulatory factor type shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-7256.
21. Perlmutter DH, Dinarello CA, Punsal PI, Cotten HR: Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expressions. J Clin Invest 1986;78:1349-1354.
22. Suva AT, Cohen J: Role of interferon-gamma in experimental gram-negative sepsis. J Infect Dis 1992;166:331-335.
23. 2 in sepsis. Blood 1990;75:1897-1898.
24. Nathan CF: Secretory products of macrophages. J Clin Invest 1987;79:319-326.
25. Vogel SN, Henricson BE: Role of cytokines as mediators of endotoxin-induced manifestations: A comparison of cytokines induced by doses of LPS and MPL that elicit comparable early endotoxin tolerance; in Nowotny A, Spitzer JJ, Ziegler EJ (eds): Endotoxin Research Series, vol 1. Cellular and Molecular Aspects of Endotoxin Reactions, 1990, pp 465-474.
26. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fancy III TS, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-474.
27. Yentis SM, Gooding RP, Riches PG: The effects of IgG and immune complexes on the endotoxin-induced cytokine response. Cytokine 1994;6:247-254.
28. Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.
29. Andersson U, Bjork L, Skansen-Saphir U, Andersson J: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42.
30. Debets JMH, van der Linden J, Dieteren IEM, Leeuwenberg JFM, Buurman WA: Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 1988;141:1197-1201.
31. Ling ZD, Ziltener HJ, Webb BT, Matheson DS: Aggregated immunoglobulin and FC fragments of IgG induce IL-6 release from human monocytes. Cell Immunol 1990;129:95-103.
32. Anegon I, Cuturi MC, Trinchieri G, Perussia B: Interaction of FC receptor (CD 16) ligands induces transcription of interleukin-2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 1988;167:452-472.
33. Chantry D, Winearls CG, Maini RN, Feldmann M: Mechanism of immune complex-mediated damage: induction of interleukin-l by immune complexes and synergy with interferon γ and tumor necrosis factor-α. Eur J Immunol 1989;19:189-192.
34. Gough DB, Jordan A, Mannick JA, Rodrick ML: Impaired cell-mediated immunity in experimental abdominal sepsis and the effect of interleukin 2. Arch Surg 1992;127:859-863.
35. Aukrust P, Froland SS, Liabakk N-B, Muller F, Nordoy I, Haug C, Espevik T: Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in-vivo. Blood 1994;84:2136-2143.
36. Bagdasarian A, Tonetta S, Harel W, Mamidi R, Whalen J: Elevated levels of cytokines and vasoactive substances in subjects with adverse reactions to IVIG administration. Intl Symp Clini Immunol, San Francisco, 1995, abstr 112.
37. Morel AM, Delaage MA: Immunoanalysis of histamine through a novel chemical derivatization. J Allergy Clin Immunol 1988;92:646-654.
38. Enander I, Matsson P, Nystrand J, et al: A new radioimmunoassay for human mast cell tryptase using monoclonal antibodies. J Immunol Meth 1991;138:39-46.
39. Scott CF, Colman RW: Sensitive antigenic determinations of high molecular weight kininogen performed by covalent coupling of capture antibody. J Lab Clin Med. 1992;119:77-85.
40. O'Donnell JL, Roberts-Thomson PJ, Ahern MJ, Bradley J: Alteration in circulating neutrophil CR3 density associated with immunoglobulin infusion. Aust NZ J Med 1988;18:95-100.
41. Ben-Chetrit E, Putterman C: Transient neutropenia induced by intravenous immune globulin. N Engl J Med 1992;326:270-271.
42. Carvalho-Costa BT, Lin M, Sole D, Carneiro-Sampaio MMS, Sorensen R, Naspitz CK: Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with antibody deficiency syndrome. Allergy Clin Immunol, 1994;4 (suppl 2): 192.
43. Kaveri SV, Dietrich G, Hurez V, et al: Intravenous immunoglobulins (IVig) in the treatment of autoimmune disease. Clin Exp Immunol 1991;86:192-198.
44. Ronda N, Hurez V, Kazatchkine MD: Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 1993;64:65-72.
45. Debré M, Bonnet M-C, Fridman W-H, et al: Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-949.
46. Honda J, Natori H, Oizumi K, Yokoyama M: A new action mechanism of intravenous immunoglobulin for idiopathic thrombocytopenic purpura. Vox Sang 1993;64:186-187.
47. Ippoliti C, Williams LA, Huber S: Toxicity of rapidly infused concentrated intravenous immunoglobulins. Clin Pharm 1992;11:1022-1026.
48. Duhem C, Dicato MA, Ries F: Side effects of intravenous immunoglobulins. Clin Exp Immunol 1994;97(suppl 1):79-83.